Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11141687 | 0.94 | ALOX5 (0.40) | CSF1REGFRALOX5PYCR1 | |
| SCHEMBL5554028 | 0.83 | PRKCI (0.50) | MGLLADAMTS4 | |
| SCHEMBL9344176 | 0.79 | IDO1 (0.47) | MKNK1MKNK2ADAMTS4PYCR1KIF11 | |
| SCHEMBL5553131 | 0.78 | PDCD1 (0.41) | NEK1 | |
| SCHEMBL18762840 | 0.76 | CHRNA7 (0.43) | ALOX5PYCR1NEK1 | |
| SCHEMBL18899612 | 0.75 | TSHR (0.48) | ALOX5PYCR1TAAR1 | |
| SCHEMBL5549443 | 0.74 | PYCR1 (0.55) | HRH3ALOX5PYCR1 | |
| SCHEMBL679970 | 0.73 | MKNK1 (0.56) | HRH3MKNK1MKNK2KIF11 | |
| SCHEMBL11310791 | 0.73 | MKNK1 (0.56) | HRH3MKNK1MKNK2KIF11 | |
| SCHEMBL24575474 | 0.72 | LPL (0.41) | MGLLPYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | CSF1R 319/4885EGFR 1706/4885MGLL 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.